Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Protean Funds Scandinavia AB reports strong July returns across strategies and highlights its edge in SMAs. See how ...

Novo Nordisk’s challenges from both a pharmaceutical giant in Lilly and the low-cost competition from compounded drugs ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

Minister for Health Carroll MacNeill said that Wegovy will be available as early as the end of 2025 as part of the HSE’s reimbursement schemes, including the Medical Card Scheme and Drugs Payment ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

New research reveals why standard weight loss advice may not work for everyone. Discover how doctors are rethinking health and what really matters for you.

In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33% ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling to lessen the budgetary squeeze from fast-rising costs.